Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorHospital General de Mexico

About this trial

The goal of this observational study is to describe the impact measured through the Odds Ratio (OR) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients measured in days of symptoms and stay; it could include any patients with a diagnosis of admission of alcohol withdrawal syndrome (AWS) who have been treated in the department of Internal Medicine for 5 years.

The main question it aims to answer is: What is the relationship between the different clinical, biochemical, and hematic factors on the duration of symptoms, morbidity, and mortality in individuals with alcohol syndrome withdrawal?

• If the patient has a greater number of risk factors, such as advanced age, a long and chronic history of alcohol consumption, the type of distillate consumed, as well as the deterioration of liver function and presence of leukocytosis and neutrophilia, then it is postulated that the duration of alcohol withdrawal syndrome will be longer.

Clinical records will be used to describe the proportion of complications associated with alcohol withdrawal syndrome including pneumonia bronchial aspiration, seizures, need for mechanical ventilation, digestive tract hemorrhage, toxic-alcoholic hepatitis, and pancreatitis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Clinical records of patients, both genders, over 18 years of age with Alcohol Withdrawal Syndrome according to the criteria for alcohol withdrawal.

Clinical records of candidates for admission for neurological monitoring and with criteria for use of sedative drugs according to the CIWA-Ar scale

Clinical records of patients containing the CIWA-Ar scale score at diagnosis

Disqualifiers

Clinical records of patients who already have a history of seizures or epilepsy

Clinical records of diabetic patients with diabetic ketoacidosis

Clinical records of patients who have not received any type of sedative treatment

Clinical records of patients with chronic liver failure or liver cirrhosis

Trial population

Clinical records (case files) of patients with an admission diagnosis of alcohol withdrawal syndrome (AWS) who have been treated in the Internal Medicine department for 5 years will be analyzed.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Study Cohort

    Other intervention

    Clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (AAS) who have been treated in the Department of Internal Medicine for 5 years.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Death

Permanent cessation of all vital functions of an organism, including irreversible stopping of the heart and breathing

Time frame
6 months
2

Morbidity

Any type of complication present during the analysis period that complicates the resolution of the condition, including serious situations.

Time frame
6 months

Secondary outcomes

1

Hospital stay

Time recorded in the clinical record of the duration of symptoms from the first clinical manifestation until the time of discharge.

Time frame
6 months
2

Duration of symptoms

Time recorded in the clinical record of the duration of symptoms from the first clinical manifestation to the description of improvement in the medical notes

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.